Total Payments
$12,796
2023 Payments
$355.59
Companies
60
Transactions
687
Medicare Patients
9,550
Medicare Billing
$1.7M
Payment Breakdown by Category
Food & Beverage$12,286 (96.0%)
Education$310.13 (2.4%)
Consulting$200.00 (1.6%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $12,286 | 677 | 96.0% |
| Education | $310.13 | 9 | 2.4% |
| Consulting Fee | $200.00 | 1 | 1.6% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $1,425 | 78 | $0 (2023) |
| Janssen Biotech, Inc. | $940.90 | 41 | $0 (2022) |
| Amgen Inc. | $835.60 | 38 | $0 (2021) |
| E.R. Squibb & Sons, L.L.C. | $752.37 | 64 | $0 (2022) |
| Eisai Inc. | $607.54 | 46 | $0 (2021) |
| GENZYME CORPORATION | $569.01 | 29 | $0 (2021) |
| NOVARTIS PHARMACEUTICALS CORPORATION | $521.39 | 28 | $0 (2021) |
| Taiho Oncology, Inc. | $503.50 | 33 | $0 (2021) |
| PFIZER INC. | $476.17 | 25 | $0 (2022) |
| Sirtex Medical Inc | $464.21 | 5 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $355.59 | 8 | Bayer Healthcare Pharmaceuticals Inc. ($200.00) |
| 2022 | $189.51 | 6 | Janssen Biotech, Inc. ($119.33) |
| 2021 | $1,489 | 79 | AstraZeneca Pharmaceuticals LP ($257.38) |
| 2020 | $1,287 | 60 | AstraZeneca Pharmaceuticals LP ($165.94) |
| 2019 | $3,263 | 207 | AstraZeneca Pharmaceuticals LP ($286.62) |
| 2018 | $3,262 | 190 | AstraZeneca Pharmaceuticals LP ($369.01) |
| 2017 | $2,951 | 137 | Sirtex Medical Inc ($295.41) |
All Payment Transactions
687 individual payment records from CMS Open Payments — Page 1 of 28
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/25/2023 | Bayer Healthcare Pharmaceuticals Inc. | Adempas (Drug) | Consulting Fee | Cash or cash equivalent | $200.00 | General |
| Category: Cardio-pulmonary | ||||||
| 09/11/2023 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $22.69 | General |
| 07/27/2023 | Astellas Pharma US Inc | Padcev (Drug) | Food and Beverage | In-kind items and services | $18.88 | General |
| Category: Oncology | ||||||
| 06/22/2023 | Mirati Therapeutics, Inc. | KRAZATI (Drug) | Food and Beverage | In-kind items and services | $23.87 | General |
| Category: ONCOLOGY | ||||||
| 06/21/2023 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $24.60 | General |
| 06/02/2023 | Astellas Pharma US Inc | Padcev (Drug) | Food and Beverage | In-kind items and services | $18.28 | General |
| Category: Oncology | ||||||
| 05/04/2023 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $24.39 | General |
| 04/07/2023 | Mirati Therapeutics, Inc. | KRAZATI (Drug) | Food and Beverage | In-kind items and services | $22.88 | General |
| Category: ONCOLOGY | ||||||
| 10/27/2022 | PFIZER INC. | LORBRENA (Drug) | Education | In-kind items and services | $15.50 | General |
| Category: ONCOLOGY | ||||||
| 08/15/2022 | PFIZER INC. | LORBRENA (Drug) | Education | In-kind items and services | $15.50 | General |
| Category: ONCOLOGY | ||||||
| 03/29/2022 | Janssen Biotech, Inc. | ERLEADA (Drug) | Food and Beverage | In-kind items and services | $19.38 | General |
| Category: Oncology | ||||||
| 03/18/2022 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $24.67 | General |
| Category: Hematology | ||||||
| 03/01/2022 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $14.51 | General |
| Category: Oncology | ||||||
| 01/14/2022 | Janssen Biotech, Inc. | ERLEADA (Drug) | Education | In-kind items and services | $99.95 | General |
| Category: Oncology | ||||||
| 12/17/2021 | Alexion Pharmaceuticals, Inc. | Ultomiris (Drug) | Food and Beverage | In-kind items and services | $11.80 | General |
| Category: Immunology | ||||||
| 12/08/2021 | GENZYME CORPORATION | SARCLISA (Biological), ELITEK | Food and Beverage | In-kind items and services | $20.53 | General |
| Category: Oncology | ||||||
| 11/24/2021 | Blue Earth Diagnostics Limited | Axumin (Drug) | Food and Beverage | In-kind items and services | $20.92 | General |
| Category: Diagnostic Imaging | ||||||
| 11/20/2021 | Genentech USA, Inc. | Phesgo (Biological) | Food and Beverage | In-kind items and services | $16.39 | General |
| Category: BioOncology | ||||||
| 11/11/2021 | Janssen Biotech, Inc. | — | Food and Beverage | In-kind items and services | $18.39 | General |
| 11/11/2021 | Takeda Pharmaceuticals U.S.A., Inc. | NINLARO (Drug) | Food and Beverage | In-kind items and services | $15.74 | General |
| Category: ONCOLOGY | ||||||
| 11/10/2021 | Ipsen Biopharmaceuticals, Inc | SOMATULINE DEPOT (Drug), ONIVYDE | Food and Beverage | In-kind items and services | $19.70 | General |
| Category: Oncology/Endocrinology | ||||||
| 11/10/2021 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Food and Beverage | In-kind items and services | $14.44 | General |
| Category: Oncology | ||||||
| 11/04/2021 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Food and Beverage | In-kind items and services | $13.92 | General |
| Category: Oncology | ||||||
| 11/03/2021 | Dendreon Pharmaceuticals LLC | PROVENGE (Drug) | Food and Beverage | In-kind items and services | $18.73 | General |
| Category: CELLULAR BIOLOGIC TREATMENT FOR PROSTATE CANCER | ||||||
| 10/30/2021 | NOVARTIS PHARMACEUTICALS CORPORATION | TABRECTA (Drug) | Food and Beverage | In-kind items and services | $17.39 | General |
| Category: ONCOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 59 | 2,856 | 40,872 | $2.1M | $588,690 |
| 2022 | 55 | 2,282 | 17,578 | $1.6M | $290,890 |
| 2021 | 60 | 2,510 | 51,391 | $3.3M | $579,973 |
| 2020 | 54 | 1,902 | 16,749 | $1.2M | $274,661 |
Total Patients
9,550
Total Services
126,590
Medicare Billing
$1.7M
Procedure Codes
228
All Medicare Procedures & Services
228 procedure records from CMS Medicare Utilization — Page 1 of 10
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2023 | 13 | 7,600 | $760,000 | $329,600 | 43.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 159 | 429 | $196,920 | $50,836 | 25.8% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 16 | 1,920 | $201,600 | $35,856 | 17.8% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 53 | 150 | $82,500 | $19,413 | 23.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 89 | 229 | $68,700 | $18,540 | 27.0% |
| J1454 | Injection, fosnetupitant 235 mg and palonosetron 0.25 mg | Office | 2023 | 15 | 44 | $92,400 | $14,814 | 16.0% |
| 88185 | Flow cytometry technique for dna or cell analysis, each additional marker | Office | 2023 | 17 | 598 | $64,584 | $13,894 | 21.5% |
| J1439 | Injection, ferric carboxymaltose, 1 mg | Office | 2023 | 16 | 13,500 | $67,500 | $11,910 | 17.6% |
| 99490 | Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2023 | 51 | 204 | $30,600 | $11,571 | 37.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 40 | 40 | $31,200 | $8,183 | 26.2% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 329 | 946 | $18,920 | $7,946 | 42.0% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 285 | 825 | $123,750 | $6,278 | 5.1% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 43 | 89 | $44,500 | $5,566 | 12.5% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 41 | 154 | $18,480 | $4,286 | 23.2% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 156 | 351 | $21,060 | $3,633 | 17.3% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 17 | 55 | $23,100 | $3,496 | 15.1% |
| 82378 | Carcinoembryonic antigen (cea) protein level | Office | 2023 | 60 | 172 | $10,320 | $3,196 | 31.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 18 | 20 | $18,800 | $3,043 | 16.2% |
| 99426 | Principal care management services for a single high-risk disease, first 30 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2023 | 11 | 51 | $11,526 | $2,890 | 25.1% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 95 | 196 | $37,240 | $2,597 | 7.0% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 39 | 136 | $12,920 | $2,014 | 15.6% |
| 88184 | Flow cytometry technique for dna or cell analysis, first marker | Office | 2023 | 17 | 26 | $7,800 | $1,918 | 24.6% |
| 86300 | Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 | Office | 2023 | 27 | 93 | $6,510 | $1,896 | 29.1% |
| 83735 | Magnesium level | Office | 2023 | 118 | 259 | $19,425 | $1,702 | 8.8% |
| 96402 | Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 15 | 51 | $6,120 | $1,687 | 27.6% |
About Dr. William Grace, M.D
Dr. William Grace, M.D is a Specialist healthcare provider based in New York, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/01/2005. The National Provider Identifier (NPI) number assigned to this provider is 1578565610.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. William Grace, M.D has received a total of $12,796 in payments from pharmaceutical and medical device companies, with $355.59 received in 2023. These payments were reported across 687 transactions from 60 companies. The most common payment nature is "Food and Beverage" ($12,286).
As a Medicare-enrolled provider, Grace has provided services to 9,550 Medicare beneficiaries, totaling 126,590 services with total Medicare billing of $1.7M. Data is available for 4 years (2020–2023), covering 228 distinct procedure/service records.
Ad
Practice Information
- Specialty Specialist
- Location New York, NY
- Active Since 06/01/2005
- Last Updated 04/25/2017
- Taxonomy Code 174400000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1578565610
Products in Payments
- OPDIVO (Biological) $567.89
- TAGRISSO (Drug) $537.32
- Lenvima (Drug) $514.68
- IMFINZI (Drug) $513.51
- SIR-Spheres Microspheres (Device) $464.21
- Lonsurf (Drug) $459.65
- JEVTANA (Drug) $436.11
- NINLARO (Drug) $392.84
- Erleada (Drug) $284.13
- IBRANCE (Drug) $283.82
- Neulasta (Biological) $280.59
- JAKAFI (Drug) $262.92
- Rubraca (Drug) $227.06
- ZEJULA (Drug) $209.28
- KEYTRUDA (Biological) $204.04
- Adempas (Drug) $200.00
- IMBRUVICA (Drug) $199.93
- SANCUSO (Drug) $199.46
- ADCETRIS (Biological) $191.70
- ERLEADA (Drug) $165.65
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Specialist Doctors in New York
Dr. Eric Rose, M.d, M.D
Specialist — Payments: $4.9M
Specialist $4.9M
Dr. Baron Lonner, M.d, M.D
Specialist — Payments: $2.9M
Specialist $2.9M
Dr. Richard Spaide, Md, MD
Specialist — Payments: $1.7M
Specialist $1.7M
Dr. Marla Dubinsky, M.d, M.D
Specialist — Payments: $1.6M
Specialist $1.6M
Mrs. Naomi Nakao, M.d, M.D
Specialist — Payments: $1.1M
Specialist $1.1M
Dr. Janice Dutcher, M.d, M.D
Specialist — Payments: $994,054
Specialist $994,054